Seek truth from facts, competitive symbiosis
06
2019-06
Hunan Zhengqing Pharmaceutical Group Co., Ltd. (hereinafter referred to as “the Company”) has obtained the approval for the non-public issuance of shares (hereinafter referred to as “this Non-Public Issuance”) to specific investors from the China Securities Regulatory Commission, as per the “Approval on the Non-Public Issuance of Shares by Hunan Zhengqing Pharmaceutical Group Co., Ltd.” (CSRC Approval [2019]2023). The approval permits the Company to non-publicly issue no more than 17,964,071 new shares and brings the Company under the supervision of non-listed public companies. The Company completed this Non-Public Issuance in November 2019, issuing a total of 17,964,071 RMB ordinary shares to 2 specific investors at an issue price of RMB 1.67 per share, raising funds totaling RMB 30,000,000, of which the newly added registered capital (share capital) is RMB 17,964,071. According to the results of this Non-Public Issuance and the authorization by the Company’s Shareholders’ Meeting, the Company has amended relevant articles of the “Articles of Association”. Article 4 of Chapter 1 has been revised to “The Company’s registered capital is RMB 70,270,346”; Article 16 of Chapter 3 has been revised to “The Company’s total share capital is 70,270,346 shares”. The Company has now completed the industrial and commercial registration procedures for the amendment of the “Articles of Association” and the change in registered capital, obtained a new “Business License”, and completed the capital increase registration procedures at Hunan Equity Registration Management Center Co., Ltd. in accordance with relevant regulations. Notice is hereby given. Hunan Zhengqing Pharmaceutical Group Co., Ltd. Board of Directors November 29, 2019
08
2017-08
Recently, Dr. Wu Feichi, Chairman of Hunan Zhengqing Group, and his delegation braved the scorching heat to visit the scientific research and teaching base of Nanyang Wenhe Orthopedic Hospital in Henan for inspection and guidance. Dean Wu Taian of Nanyang Wenhe Orthopedic Hospital, Manager Li Xinguo of Nanyang Puqiang Pharmaceutical Co., Ltd., the Nanyang general distributor, and relevant leaders and experts participated in the reception.
![[Hunan Satellite TV News Broadcast] Bater came to Hunan for investigation to innovate reproducible and scalable poverty alleviation models.](https://omo-oss-image.thefastimg.com/portal-saas/pg2025063012344964515/cms/image/b4335961-daa8-440b-ae35-a54c7cb5ae82.jpeg "[Hunan Satellite TV News Broadcast] Bater came to Hunan for investigation to innovate reproducible and scalable poverty alleviation models.")
06
2017-06
From May 17th to 19th, Bater, Deputy Head of the United Front Work Department of the CPC Central Committee, Director of the National Ethnic Affairs Commission, and Secretary of its Party Leadership Group, led a delegation to Hunan to conduct research on ethnic affairs and regional development and poverty alleviation work in the Wuling Mountain area. During the visit, Du Jiahao, Secretary of the Provincial Party Committee and Director of the Standing Committee of the Provincial People's Congress, held discussions with Bater and his delegation.
![[Industry Interview] Zhengqing Pharmaceutical Chairman Wu Feichi: Aggregating Resources to Build a National Brand in the Rheumatism and Pain Market](https://omo-oss-image.thefastimg.com/portal-saas/pg2025063012344964515/cms/image/240b33c2-e566-4d1a-b821-7144549d0708.jpeg "[Industry Interview] Zhengqing Pharmaceutical Chairman Wu Feichi: Aggregating Resources to Build a National Brand in the Rheumatism and Pain Market")
06
2017-06
[Menet.com] Building a brand is a reflection of a country's economic capability, an industry's creative ability, and even an entrepreneur's vision and pursuit. In the pharmaceutical industry, shaping products into national brands holds even greater significance, as we have trodden the path of 'wild' growth and imitation for too many years. When we finished interviewing Wu Feichi, Chairman of Zhengqing Pharmaceutical Group, we found that this elegant, rigorous entrepreneur, who started as a pharmaceutical engineer, has a special affection for the Zhengqing Fengtongning series products. This affection concerns the entrepreneur's values, the company's future, and even more so, the rise of national brands in the rheumatism and pain medication market.
![[China Traditional Chinese Medicine News] Public Hospitals Returning to Public Welfare Is Not the Panacea for Medical Reform—A Discussion with Academician Zhong Nanshan](https://omo-oss-image.thefastimg.com/portal-saas/pg2025063012344964515/cms/image/e8b1dff1-f4db-49e9-bf21-0988ffbf0287.jpeg "[China Traditional Chinese Medicine News] Public Hospitals Returning to Public Welfare Is Not the Panacea for Medical Reform—A Discussion with Academician Zhong Nanshan")
11
2015-11
During this year's Two Sessions, Zhong Nanshan, a national people's congress representative and academician of the Chinese Academy of Engineering, proposed that "public hospitals should return to their public welfare nature; this is the crux of medical reform." Mr. Zhong Nanshan is my teacher, and I respect him very much. Aristotle once said, "I love my teacher, but I love the truth even more." As someone who has worked in the pharmaceutical industry for over 20 years, I disagree with Mr. Zhong Nanshan's view on medical reform.
07
2014-07
Waiting shines brightly because of hope
Our reporter (Correspondent Yang Lijun) "Zhengqing is indeed a responsible enterprise. After nearly 20 years, they are still confirming equity, which not only gives us hope but also makes us trust this company more." "We've held the shares for nearly 20 years, and their intrinsic value is no longer important to us. What excites us about this equity confirmation is not the monetary value, but Zhengqing Group's sense of responsibility towards its shareholders." ...At the equity confirmation sites in Changsha and Hengyang, many shareholders excitedly shared and exchanged their thoughts.
Copyright Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Virtual Showroom：
Agent：
OA：
CRM：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： Hunan Zhengqing Pharmaceutical Group Co., Ltd.
表单验证提示文本： Please enter correct content!
循环体没有内容时： Updating......
CSS / JS 文件放置地